Mezagitamab is a human IgG1 monoclonal antibody directed against CD38, a cell surface molecule highly expressed on myeloma cells, plasma cells, plasmablasts, and natural killer (NK) cells, and is induced on activated T cells and other suppressor cells including regulatory T (Tregs) and B (Bregs) cells.